The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy
Abstract
In multiple myeloma (MM), previous studies showed that mutations of the p53 gene are rare events in patients with newly diagnosed disease, but it is not known whether deletions of p53 are of any significance in MM. To address this question, we used interphase fluorescence in situ hybridization (FISH) with a DNA probe specific for the p53 locus at 17p13 and investigated bone marrow plasma cells from 72 patients with MM (59 patients = 81.9% before therapy). By FISH, deletions of p53, which were found to be predominantly monoallelic, were detected in 32.8% and 54.5% of patients with newly diagnosed and relapsed MM, respectively. Karyotypes from six of the patients with a p53 deletion by FISH showed a structural abnormality of 17p in only one of them. Additional FISH studies including a distal-17p probe (specific for theD17S34 locus) provided evidence for an interstitial deletion on 17p resulting in loss of p53 hybridization signals in myeloma cells. Among all 59 patients with newly diagnosed MM, presence of a p53 deletion was associated with stage III (P = .054), but not with other laboratory and clinical parameters. Patients with a p53 deletion had significantly shorter survival time compared with those without a deletion, both from the time of diagnosis (median 13.9v 38.7 months; P < .0001) and from the time of initiation of induction treatment consisting of conventional dose chemotherapy (median 15.9 months v median not reached at 38 months; P < .0002). On stepwise multivariate regression analysis, presence of a p53 deletion was the most significant independent parameter predicting for shortened survival (P = .002). We conclude that a p53 gene deletion, which can be identified by interphase FISH in almost a third of patients with newly diagnosed MM, is a novel prognostic factor predicting for short survival of MM patients treated with conventional-dose chemotherapy. © 1998 by The American Society of Hematology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862
Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., et al. (1995) · Blood · doi:10.1182/blood.v85.6.1580.bloodjournal8561580 · Cited by 732
Localization of gene for human p53 tumour antigen to band 17p13
Isobe, M., Emanuel, B. S., Givol, D., Oren, M., & Croce, C. M. (1986) · Nature · doi:10.1038/320084a0 · Cited by 485
Schweizer, D. (1980) · Cytogenetic and Genome Research · doi:10.1159/000131482 · Cited by 465
Dewald, G., Kyle, R., Hicks, G., & Greipp, P. (1985) · Blood · doi:10.1182/blood.v66.2.380.380 · Cited by 401
Tricot, G., Barlogie, B., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S., & Sawyer, Jr. (1995) · Blood · doi:10.1182/blood.v86.11.4250.bloodjournal86114250 · Cited by 395
Multifactorial analysis of p53 alteration in human cancer: A review
Soussi, T., Legros, Y., Lubin, R., Ory, K., & Schlichtholz, B. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570102 · Cited by 353
堀尾, 芳. (1995) · Medical Entomology and Zoology · doi:10.11501/3102283 · Cited by 352
Cytogenetic findings in 200 patients with multiple myeloma
Sawyer, J. R., Waldron, J. A., Jagannath, S., & Barlogie, B. (1995) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)00284-i · Cited by 343
Lotem, J., & Sachs, L. (1993) · Blood · doi:10.1182/blood.v82.4.1092.1092 · Cited by 301
Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma
Ichikawa, A., Kinoshita, T., Watanabe, T., Kato, H., Nagai, H., Tsushita, K., Saito, H., & Hotta, T. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708213370804 · Cited by 274
Counterstain-enhanced chromosome banding
Schwezer, D. (1981) · Human Genetics · doi:10.1007/bf00271159 · Cited by 246
Lai, J., Zandecki, M., Mary, J., Bernardi, F., Izydorczyk, V, Flactif, M., Morel, P., Jouet, J., Bauters, F., & Facon, T. (1995) · Blood · doi:10.1182/blood.v85.9.2490.bloodjournal8592490 · Cited by 216
p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy
Neri, A., Baldini, L., Trecca, D., Cro, L., Polli, E., & Maiolo, A. (1993) · Blood · doi:10.1182/blood.v81.1.128.128 · Cited by 199
Laï, J., Preudhomme, C., Zandecki, M., FLACTIF, M., Vanrumbeke, M., Lepelley, P., Wattel, E., & Fenaux, P. (1995) · PubMed · Cited by 197
Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia
Okuda, T., Shurtleff, S., Valentine, M., Raimondi, S., Head, D., Behm, F., Curcio- Brint, A., Liu, Q., Pui, C., & Sherr, C. (1995) · Blood · doi:10.1182/blood.v85.9.2321.bloodjournal8592321 · Cited by 192
Drach, J. W., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fiegl, M., Rothermundt, C. A., Gsur, A., Jaeger, U., & Heinz, R. (1995) · PubMed · Cited by 192
Self-citationTricot, G., Sawyer, J. R., Jagannath, S., Desikan, K. R., Siegel, D., Naucke, S., Mattox, S., Bracy, D., Munshi, N., & Barlogie, B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2659 · Cited by 172
Carson, D. A., & Lois, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91693-8 · Cited by 172
Calasanz, M. J., Cigudosa, J. C., Odero, M. D., Ferreira, C., Ardanaz, M. T., Fraile, A., Carrasco, J. L., Solé, F. G., Cuesta, B., & Gullón, A. (1997) · Genes Chromosomes and Cancer · Cited by 156
MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL
Zandecki, M., Laï, J. L., & Facon, T. T. F. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.d01-2939.x · Cited by 148
p53 and RAS gene mutations in multiple myeloma.
Portier, M., Molès, J., Mazars, G. R., Jeanteur, P., Bataille, R., Klein, B., & Theillet, C. G. (1992) · PubMed · Cited by 145
Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius, S., Børresen‐Dale, A., & Eyfjörd, J. E. (1993) · PubMed · Cited by 119
Höglund, M., Johansson, B., Pedersen-Bjergaard, J., Marynen, P., & Mitelman, F. (1996) · Blood · doi:10.1182/blood.v87.1.324.bloodjournal871324 · Cited by 115
MDM2 Protein Overexpression Promotes Proliferation and Survival of Multiple Myeloma Cells
Teoh, G., Urashima, M., Ogata, A., Chauhan, D., DeCaprio, J. A., Treon, S. P., Schlossman, R. L., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v90.5.1982 · Cited by 106
Preudhomme, C., & Fenaux, P. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2403057.x · Cited by 106
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.
Corradini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P. F., Gu, W. J., Nilsson, K., Knowles, D. M., II, & Boccadoro, M. (1994) · PubMed · Cited by 103
Avet‐Loiseau, H., Andree-Ashley, L. E., Moore, D. H., Mellerin, M., Feusner, J. D., Bataille, R., & Pallavicini, M. G. (1997) · Genes Chromosomes and Cancer · Cited by 97
Kobayashi, H., Montgomery, K., Bohlander, S. K., Adra, C., Lim, B., Kucherlapati, R. S., Donis-Keller, H., Holt, M., Beau, M. M. L., & Rowley, J. (1994) · Blood · doi:10.1182/blood.v84.10.3473.3473 · Cited by 89
Karyotype in multiple myeloma and plasma cell leukaemia
Weh, H. J., Gutensohn, K., Selbach, J., Kruse, R., Wacker-Backhaus, G., Seeger, D. R., Fiedler, W., Fett, W., & HOSSFELD, D. K. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90071-m · Cited by 84
FLACTIF, M., Zandecki, M., Laï, J. L., et al. (1995) · PubMed · Cited by 83
Rare occurrence of P53 gene mutations in multiple myeloma
Preudhomme, C., Facon, T. T. F., Zandecki, M., Vanrumbeke, M., Laı̈, J. L., Nataf, E., Loucheux‐Lefebvre, M. H., Kerckaert, J. P., & Fenaux, P. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08253.x · Cited by 73
Andreasson, P., Johansson, B., Arheden, K., Billström, R., Mitelman, F., & Höglund, M. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199706)19:2<77::aid-gcc2>3.0.co;2-x · Cited by 42
Kobayashi, H., & Rowley, J. D. (1995) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870120112 · Cited by 40
Włodarska, I., Marynen, P., Starza, R. L., Mecucci, C., & BERGHE, H. V. D. (2008) · Cytogenetics and Cell Genetics · doi:10.1159/000134197 · Cited by 36
Chromosomes in plasma-cell malignancies.
BERGHE, H. V. D. (1989) · PubMed · Cited by 25
Willems, P. M. W., Kuypers, A. W. H. M., Meijerink, J. P. P., et al. (1993) · PubMed · Cited by 23
Cited by
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Self-citationGenetics and Cytogenetics of Multiple Myeloma
Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J., Greipp, P. R., Kirsch, I. R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2876 · Cited by 687
Self-citationClinical and biologic implications of recurrent genomic aberrations in myeloma
Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M. M., Kyle, R. A., Dewald, G. W., Van Ness, B., Van Wier, S. A., Henderson, K. J., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3017 · Cited by 660
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Metadata
- Authors
- Drach, J., Ackermann, J., Fritz, E., Krömer, E., Schuster, R., Gisslinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., Schuster, J., Heinz, R., Ludwig, H., & Huber, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-08-01
- Volume
- 92
- Issue
- 3
- Pages
- 802-809
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2127096655
- Cited by
- 325
- References
- 40
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.